Oral TQB3473 Achieves a 56.8% Response Rate in Relapsed/Refractory ITP – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Bingjie Ding et al, adding:
”TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study
This phase 1 trial found oral TQB3473 achieved a 56.8% response rate in relapsed/refractory ITP, with 600 mg daily showing the best efficacy-tolerability balance.”
Title: TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study
Authors: Bingjie Ding, Tiejun Gong, Xiangzhou Du, Xiaoming Li, Yinghui Lai, Zhenyu Yan, Rong Fu, Xin Du, Anqi Yang, Jiajia Zhu, Yiran Wang, Hu Zhou

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke